Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Intuniv XR | Guanfacine hydrochloride | Attention-deficit/hyperactivity disorder (ADHD) | Do not list | Complete | ||
| Neupro | Rotigotine | Parkinson's disease | Do not list | Complete | ||
| Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
| Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete | ||
| Afinitor | Everolimus | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex | Do not list | Complete | ||
| Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | ||
| Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete |
Last Updated : May 20, 2024